Acceptance of the application is based on encouraging results from the Phase III CheckMate-67T study, which demonstrated non-inferiority between the oral and intravenous formulations of Opdivo.
FDA accepts Bristol-Myers Squibb’s biologics license application for subcutaneous Opdivo in all previous indications
Leave a comment
